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Abstract
Background: The management of unresectable or metastatic gastrointestinal stromal tumors (GISTs) has
previously been difficult as they are resistant to conventional chemotherapy and radiation. The
development of imatinib mesylate has made a major impact on the management of advanced GISTs. It is
apparent that there are sanctuary sites such as the central nervous system where imatinib does not achieve
adequate concentrations. We describe the case of a man with metastatic GIST who experienced multiple
cerebral relapses of disease while systemic disease progression appeared to be controlled by imatinib.
Case presentation: A 47-year-old man presented in July 1999 with a jejunal GIST with multiple hepatic
metastases. The jejunal primary was resected and after unsuccessful cytoreductive chemotherapy, the liver
metastases were also resected in December 1999. The patient subsequently relapsed in August 2001 with
symptomatic hepatic, subcutaneous gluteal, left choroidal and right ocular metastases all confirmed on CT
and PET scanning. Biopsy confirmed recurrent GIST. MRI and lumbar puncture excluded central nervous
system involvement. The patient was commenced on imatinib 400 mg bd in September 2001 through a
clinical trial.
The symptoms improved with objective PET and CT scan response until December 2002 when the patient
developed a right-sided foot drop. MRI scan showed a left parasagittal tumor which was resected and
confirmed histologically to be metastatic GIST. Imatinib was ceased pre-operatively due to the trial
protocol but recommenced in February 2003 on a compassionate use program. The left parasagittal
metastasis recurred and required subsequent re-excision in September 2003 and January 2004. Control
of the systemic GIST was temporarily lost on reduction of the dose of imatinib (due to limited drug supply)
but on increasing the dose back to 800 mg per day, systemic disease was stabilized for a period of time
before generalised progression occurred.
Conclusion: This case illustrates that the brain can be a sanctuary site to treatment of GISTs with
imatinib. Maintaining dosing of imatinib in the face of isolated sites of disease progression is also important,
as other metastatic sites may still be sensitive.
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Gastrointestinal stromal tumors (GISTs) are rare mesen-
chymal gastrointestinal tumors which can have an aggres-
sive course. Management of these tumors apart from
surgical resection has been difficult in the past because
they are resistant to conventional chemotherapy [1] and
radiation. The development of imatinib mesylate [2] a
receptor tyrosine kinase inhibitor has made a major
impact on the management of advanced GISTs. It specifi-
cally targets the c-kit (CD117) proto-oncogene gain of
function mutation characterising GISTs, blocking the c-kit
kinase, leading to growth cessation and significant dura-
ble clinical remissions. This oral drug is also active in all
phases of chronic myeloid leukemia (CML) as it also tar-
gets the bcr-abl tyrosine kinase. It is apparent that there are
sanctuary sites such as the central nervous system where
imatinib does not achieve adequate concentrations. We
describe the case of a man with metastatic GIST who expe-
rienced multiple cerebral relapses of disease while sys-
temic disease progression appeared to be controlled by
imatinib.
Case presentation
A 47-year-old man presented in July 1999 with melena. A
small bowel series and CT abdomen showed a jejunal
mass and a 5 × 5 cm complex hepatic mass. A biopsy of
the liver lesion revealed a spindle cell tumor. Laparotomy
was performed, and the 7.5 cm jejunal mass was resected.
A total of 4 liver lesions were noted, but not resected. The
histopathology confirmed a gastrointestinal stromal
tumor with clear resection margins. He subsequently had
4 cycles of attempted cytoreductive chemotherapy using
doxorubicin and dacarbazine. A repeat CT scan showed
progression of the liver metastases. An extended right
hemihepatectomy was performed in December 1999 with
successful excision of all 4 liver metastases.
The patient remained well until review in August 2001
when he complained of lethargy, right upper quadrant
abdominal pain, diplopia and blurred vision in the left
eye. Examination revealed weakness of the right lateral
rectus ocular muscle, an amelanotic left choroidal lesion,
hepatomegaly and a subcutaneous nodule in the gluteal
region. An enhancing lesion in the infero-lateral region of
the right globe was confirmed on CT which was thought
to be the cause of the ocular muscle weakness. The CT
scan also demonstrated a recurrence of multiple hepatic
metastases. There were no intracerebral lesions. The glu-
teal lesion was biopsied and confirmed recurrence of GIST
(CD117 positive). A positron emission tomogram (PET)
scan also confirmed disease recurrence in the same distri-
bution. Lumbar puncture and MRI scan of the brain
excluded the presence of leptomeningeal or cerebral
metastases. The patient was commenced on imatinib
mesylate (STI-571, Gleevec, Novartis) 400 mg bd in Sep-
tember 2001 as part of a clinical trial. He felt much
improved by November 2001 when a repeat CT abdomen
showed stable disease but PET scan now showed no FDG
uptake. By January 2002 his diplopia had completely
resolved but the left-sided choroidal lesion remained
unchanged on fundoscopy. The buttock lesion had also
resolved.
A progress CT in December 2002 showed minor enlarge-
ment of one of the liver lesions. A PET scan however con-
tinued to show no areas of abnormal FDG uptake. The
patient at that time had developed a right-sided foot drop.
MRI of the brain and spine demonstrated a left parasagit-
tal tumor with radiographic features consistent with a
meningioma (see Figure 1). Imatinib was ceased preoper-
atively as per the trial protocol. A craniotomy was per-
formed on the 28th January 2003 with complete resection
of the lesion. Histopathology demonstrated metastatic
GIST (CD117 positive) (see Figures 2 and 3). Post opera-
tively the patient developed recurrent diplopia (due to
recurrent right lateral rectus weakness) with blurred vision
off imatinib. This was recommenced at a dose of 400 mg
bd on the 14th February 2003 after being ceased 6 weeks
earlier because of the documented disease progression in
the brain as required by the trial protocol. Drug supply
was obtained through a compassionate use program.
Repeat fundoscopy in February 2003 showed the choroi-
dal lesion had enlarged. His foot drop persisted, however
his diplopia again had completely resolved by March
2003.
Mutational analysis on the tumor blocks was carried out.
An in-frame GCCTAT insertion/duplication in exon 9 of c-
kit in the original jejunal tumor, the liver and the cerebral
metastases were detected (See Figure 4). No mutations
were found in exons 11, 13 or 17 in any of the samples.
Due to limited drug supply available on compassionate
use (pending local approval for reimbursement), the
patient's dose of imatinib mesylate was reduced to 400
mg per day in March 2003. Six weeks later, his diplopia
had returned and a progress CT abdomen demonstrated a
minor progression of the liver lesions. His liver function
tests remained normal. A subsequent PET scan again
showed no abnormal uptake despite disease progression
on the CT scan. His dose of imatinib mesylate was
increased initially to 600 mg per day with resolution of
the diplopia.
By May 2003 his foot drop had worsened and his dose of
imatinib mesylate was increased back to 800 mg per day.
Despite the increase in dose, his foot drop worsened. A
repeat CT brain demonstrated a recurrence of the cerebral
metastasis with surrounding vasogenic oedema in the pre-
vious site of resection. A repeat abdominal CT showed noPage 2 of 7
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mild shrinking of the nodule in the buttock.
Due to limited treatment options available for the cere-
bral metastasis, a re-resection of the cranial metastasis was
Sagittal MRI image of brain at first cerebral relapse demonstrating an enhancing left parasagittal lesion with surrounding cere-bral oedemaFi ur  1
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firmed the presence of the left parasagittal lesion with
surrounding edema but no mass effect. Repeat craniot-
omy and incomplete debulking of the parasagittal metas-
tasis was performed on the 9th September 2003. A small
residual area of tumor was seen on the postoperative scan.
Abdominal imaging two months later showed that two of
the liver lesions had increased in size with the other areas
stable. He was not a candidate for further hepatic resec-
tion as there was insufficient liver reserve due to the past
surgery. Radiofrequency ablation was declined as the
patient did not have symptoms referable to the area.
The patient remained well until December 2003 when he
experienced symptoms of headaches, worsening diplopia,
right foot drop and left arm weakness. MRI scan con-
firmed recurrence of the cerebral metastasis with exten-
sion across the falx cerebri. He declined cranial
radiotherapy treatment at the time and instead underwent
a third resection of the lesion in January 2004 where
incomplete debulking was achieved with early improve-
ment of his limb weakness. In April 2004 the patient
enrolled into a randomised placebo controlled clinical
trial of a novel multi-kinase inhibitor SU-11248 (Pfizer)
for the treatment of imatinib refractory GIST. However his
condition slowly deteriorated and he died in July 2004.
Discussion
This case illustrates a man who has had evidence of pre-
sumed ocular involvement by the GIST that initially
responded to imatinib who had a cranial relapse while the
systemic disease initially remained controlled. This would
Photomicrograph of cerebral metastases showing sheets of epithelioid and spindle cells, (H&E × 200)Figure 2
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site where the imatinib mesylate does not achieve
adequate levels. Preclinical mice models of CML have
shown development of central nervous involvement on
imatinib despite systemic disease control with cerebral
spinal fluid levels being 155 times lower than plasma [3].
This is supported by clinical data from treatment of CML,
where isolated cerebral relapses [4,5] have been described
and low cerebrospinal fluid (CSF) levels of imatinib
mesylate documented during therapy with the drug [6].
One case of cerebral metastases from advanced GIST
responding to imatinib mesylate has been published [7].
We would postulate that the blood brain barrier might be
disrupted in some individuals thereby allowing better
penetration of the drug to the brain. However in those
individuals with good systemic disease control, the central
nervous system may represent a sanctuary site for imatinib
sensitive disease to progress.
There appears to be a relationship between the presence of
different activating kinase mutations of kit and clinical
outcomes of GISTs on imatinib [8]. The exon 9 mutation
encoding the extracellular domain occurs in approxi-
mately 15% of GISTs resulting in duplication of Ala502
and Tyr503 This may be marker for malignant course of the
disease as 71% have a highly malignant course and 59%
arise exclusively in the small intestine [9]. Patients with
exon 9 mutations also have a much worse prognosis than
those with the more commonly found exon 11 mutations
[8]. The difference is likely to be due to differences in
Immunohistochemical stain for CD117 (c-kit) showing staining of the cell membrane and Golgi region of the tumor cells, (× 400)Figure 3
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susceptibility of the GIST to imatinib and in our case may
have compounded the problem with reduced CSF levels
of the drug. Exon 17 mutations have been found in some
DNA sequence of part of exon 9 of c-kit for control (lower) and patient tumour (upper) samplesFigure 4
DNA sequence of part of exon 9 of c-kit for control (lower) and patient tumour (upper) samples. The patient's tumour sample 
contained a GCCTAT duplication
Wild  CTGCCTATTTTAACTTTGCAT
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GISTs that have relapsed on imatinib and are thought to
be a mechanism of acquired resistance [10]. The absence
of this superadded mutation would lend support to the
central nervous system in being a sanctuary site in this
patient.
Conclusions
The central nervous system can be a sanctuary site to treat-
ment of GIST with imatinib mesylate. Prolonged control
of the recurrences in this location was achieved by
repeated resections. This patient also highlights the
importance of maintaining dosing of imatinib mesylate in
the face of isolated sites of disease progression, as other
metastatic sites may still be sensitive. Cessation and low-
ering of the dose of the drug led to temporary loss of sys-
temic control in this case.
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